vs
Side-by-side financial comparison of SEALED AIR CORP (SEE) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.4B, roughly 1.7× SEALED AIR CORP). Zoetis runs the higher net margin — 25.3% vs 3.1%, a 22.1% gap on every dollar of revenue. On growth, Zoetis posted the faster year-over-year revenue change (3.0% vs 2.6%). Zoetis produced more free cash flow last quarter ($732.0M vs $257.7M). Over the past eight quarters, Zoetis's revenue compounded faster (4.4% CAGR vs 2.7%).
Sealed Air Corporation is a global provider of innovative packaging and protective solutions. Its core offerings include cushioning materials, food safety and preservation packaging, and sustainable waste-reducing packaging systems, serving retail, e-commerce, food and beverage, and industrial manufacturing markets worldwide.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
SEE vs ZTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.4B | $2.4B |
| Net Profit | $43.8M | $603.0M |
| Gross Margin | 28.6% | 70.2% |
| Operating Margin | 11.4% | 31.9% |
| Net Margin | 3.1% | 25.3% |
| Revenue YoY | 2.6% | 3.0% |
| Net Profit YoY | 700.0% | 3.8% |
| EPS (diluted) | $0.30 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.4B | $2.4B | ||
| Q3 25 | $1.3B | $2.4B | ||
| Q2 25 | $1.3B | $2.5B | ||
| Q1 25 | $1.3B | $2.2B | ||
| Q4 24 | $1.4B | $2.3B | ||
| Q3 24 | $1.3B | $2.4B | ||
| Q2 24 | $1.3B | $2.4B | ||
| Q1 24 | $1.3B | $2.2B |
| Q4 25 | $43.8M | $603.0M | ||
| Q3 25 | $255.1M | $721.0M | ||
| Q2 25 | $93.1M | $718.0M | ||
| Q1 25 | $113.5M | $631.0M | ||
| Q4 24 | $-7.3M | $581.0M | ||
| Q3 24 | $91.7M | $682.0M | ||
| Q2 24 | $98.3M | $624.0M | ||
| Q1 24 | $82.0M | $599.0M |
| Q4 25 | 28.6% | 70.2% | ||
| Q3 25 | 29.8% | 71.5% | ||
| Q2 25 | 30.7% | 73.6% | ||
| Q1 25 | 30.9% | 72.0% | ||
| Q4 24 | 30.0% | 69.5% | ||
| Q3 24 | 30.1% | 70.6% | ||
| Q2 24 | 31.2% | 71.7% | ||
| Q1 24 | 30.3% | 70.6% |
| Q4 25 | 11.4% | 31.9% | ||
| Q3 25 | 13.8% | 37.0% | ||
| Q2 25 | 15.0% | 36.7% | ||
| Q1 25 | 14.5% | 36.5% | ||
| Q4 24 | 11.7% | 31.6% | ||
| Q3 24 | 13.9% | 36.6% | ||
| Q2 24 | 15.4% | 33.0% | ||
| Q1 24 | 14.0% | 34.1% |
| Q4 25 | 3.1% | 25.3% | ||
| Q3 25 | 19.0% | 30.0% | ||
| Q2 25 | 7.0% | 29.2% | ||
| Q1 25 | 9.0% | 28.4% | ||
| Q4 24 | -0.5% | 25.1% | ||
| Q3 24 | 6.9% | 28.6% | ||
| Q2 24 | 7.4% | 26.4% | ||
| Q1 24 | 6.2% | 27.4% |
| Q4 25 | $0.30 | $1.37 | ||
| Q3 25 | $1.73 | $1.63 | ||
| Q2 25 | $0.63 | $1.61 | ||
| Q1 25 | $0.77 | $1.41 | ||
| Q4 24 | $-0.05 | $1.29 | ||
| Q3 24 | $0.63 | $1.50 | ||
| Q2 24 | $0.67 | $1.37 | ||
| Q1 24 | $0.56 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $344.0M | — |
| Total DebtLower is stronger | $3.3B | — |
| Stockholders' EquityBook value | $1.2B | $3.3B |
| Total Assets | $7.0B | $15.5B |
| Debt / EquityLower = less leverage | 2.65× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $344.0M | — | ||
| Q3 25 | $282.5M | $2.1B | ||
| Q2 25 | $354.4M | $1.4B | ||
| Q1 25 | $335.2M | $1.7B | ||
| Q4 24 | $371.8M | $2.0B | ||
| Q3 24 | $386.0M | $1.7B | ||
| Q2 24 | $388.6M | $1.6B | ||
| Q1 24 | $352.8M | $2.0B |
| Q4 25 | $3.3B | — | ||
| Q3 25 | $4.0B | — | ||
| Q2 25 | $4.0B | — | ||
| Q1 25 | $4.2B | — | ||
| Q4 24 | $4.2B | — | ||
| Q3 24 | $4.3B | — | ||
| Q2 24 | $4.4B | — | ||
| Q1 24 | $4.5B | — |
| Q4 25 | $1.2B | $3.3B | ||
| Q3 25 | $1.2B | $5.4B | ||
| Q2 25 | $953.1M | $5.0B | ||
| Q1 25 | $797.9M | $4.7B | ||
| Q4 24 | $624.5M | $4.8B | ||
| Q3 24 | $771.2M | $5.2B | ||
| Q2 24 | $650.1M | $5.0B | ||
| Q1 24 | $598.3M | $5.1B |
| Q4 25 | $7.0B | $15.5B | ||
| Q3 25 | $7.1B | $15.2B | ||
| Q2 25 | $7.2B | $14.5B | ||
| Q1 25 | $7.0B | $14.1B | ||
| Q4 24 | $7.0B | $14.2B | ||
| Q3 24 | $7.3B | $14.4B | ||
| Q2 24 | $7.3B | $14.2B | ||
| Q1 24 | $7.2B | $14.3B |
| Q4 25 | 2.65× | — | ||
| Q3 25 | 3.34× | — | ||
| Q2 25 | 4.18× | — | ||
| Q1 25 | 5.26× | — | ||
| Q4 24 | 6.72× | — | ||
| Q3 24 | 5.62× | — | ||
| Q2 24 | 6.81× | — | ||
| Q1 24 | 7.49× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $293.6M | $893.0M |
| Free Cash FlowOCF − Capex | $257.7M | $732.0M |
| FCF MarginFCF / Revenue | 18.5% | 30.7% |
| Capex IntensityCapex / Revenue | 2.6% | 6.7% |
| Cash ConversionOCF / Net Profit | 6.70× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $458.5M | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $293.6M | $893.0M | ||
| Q3 25 | $165.9M | $938.0M | ||
| Q2 25 | $136.6M | $486.0M | ||
| Q1 25 | $31.9M | $587.0M | ||
| Q4 24 | $244.2M | $905.0M | ||
| Q3 24 | $170.5M | $951.0M | ||
| Q2 24 | $188.2M | $502.0M | ||
| Q1 24 | $125.1M | $595.0M |
| Q4 25 | $257.7M | $732.0M | ||
| Q3 25 | $119.6M | $805.0M | ||
| Q2 25 | $93.2M | $308.0M | ||
| Q1 25 | $-12.0M | $438.0M | ||
| Q4 24 | $185.1M | $689.0M | ||
| Q3 24 | $115.2M | $784.0M | ||
| Q2 24 | $129.5M | $370.0M | ||
| Q1 24 | $78.0M | $455.0M |
| Q4 25 | 18.5% | 30.7% | ||
| Q3 25 | 8.9% | 33.5% | ||
| Q2 25 | 7.0% | 12.5% | ||
| Q1 25 | -0.9% | 19.7% | ||
| Q4 24 | 13.6% | 29.7% | ||
| Q3 24 | 8.6% | 32.8% | ||
| Q2 24 | 9.7% | 15.7% | ||
| Q1 24 | 5.9% | 20.8% |
| Q4 25 | 2.6% | 6.7% | ||
| Q3 25 | 3.4% | 5.5% | ||
| Q2 25 | 3.3% | 7.2% | ||
| Q1 25 | 3.5% | 6.7% | ||
| Q4 24 | 4.4% | 9.3% | ||
| Q3 24 | 4.1% | 7.0% | ||
| Q2 24 | 4.4% | 5.6% | ||
| Q1 24 | 3.6% | 6.4% |
| Q4 25 | 6.70× | 1.48× | ||
| Q3 25 | 0.65× | 1.30× | ||
| Q2 25 | 1.47× | 0.68× | ||
| Q1 25 | 0.28× | 0.93× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | 1.86× | 1.39× | ||
| Q2 24 | 1.91× | 0.80× | ||
| Q1 24 | 1.53× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SEE
| Protective Segment | $1.1B | 78% |
| Other | $292.0M | 21% |
| Pension Plans Defined Benefit | $7.9M | 1% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
